Used along with diet and exercise, INVOKANA® is the first in the latest class of diabetes medicines (SGLT2 inhibitors) that’s proven to significantly lower A1C in adults living with type 2 diabetes.
The starting dose of INVOKANA® is 100 mg. Januvia® is a registered trademark of Merck Sharp & Dohme Corp.
Results may vary by dose and when used alone or with certain other diabetes medications.
Results may vary by dose and when used alone or with metformin, sitagliptin, or insulin.
As recommended by the American Diabetes Association.